Last reviewed · How we verify
Intermediate metabolisers
Intermediate metabolisers is not a drug but a pharmacogenetic classification describing individuals with moderate capacity to metabolize certain medications via cytochrome P450 enzymes.
At a glance
| Generic name | Intermediate metabolisers |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This term refers to a patient phenotype rather than a therapeutic agent. Intermediate metabolisers have heterozygous or reduced-function variants in drug-metabolizing enzymes (commonly CYP2D6, CYP2C19, or others), resulting in slower drug metabolism than extensive metabolisers but faster than poor metabolisers. This classification is used for dose optimization and safety monitoring of drugs dependent on these pathways.
Approved indications
Common side effects
Key clinical trials
- Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease. (PHASE4)
- Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers (PHASE1)
- Metabolism of Anthocyanins and Heart Health (NA)
- Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome (PHASE4)
- Pharmacokinetic Interaction Between AZD3480 and Donepezil (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intermediate metabolisers CI brief — competitive landscape report
- Intermediate metabolisers updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI